[Expression of YARS1 in hepatocellular carcinoma and its prognostic effect].

To explore the expression of , the subform of protein-based tRNA synthase (), and its prognostic effect on the analysis of gene set enrichment in hepatocellular carcinoma The expressional condition of the gene in tumor tissue samples (374 cases) and adjacent tissue samples (50 cases) of hepatocellular carcinoma patients was compared and recorded by mining the Cancer Genome Atlas database. Hepatocellular carcinoma patients were divided into high expression and low expression groups according to this data. Logistic regression was used to analyze the relationship between and the clinical pathological characteristics of hepatocellular carcinoma patients. The effect of expression on the prognosis of hepatocellular carcinoma patients was analyzed by the Kaplan-Meier method and log-rank test. The prognostic value of the gene for hepatocellular carcinoma was analyzed by univariate and multivariate Cox regression. Gene set enrichment analysis was used to evaluate the gene pathways related to in the occurrence and development of hepatocellular carcinoma. The expression of the gene was higher in hepatocellular carcinoma tissue than in normal tissue (<0.001). The expression level of was correlated with the grade of patients (<0.05), but not with age, gender, TNM stage, and others (>0.05). The results of Kaplan-Meier method and log-rank test showed that the survival rate was lower in patients with high gene expression than that of patients with low gene expression (<0.001). The results of multivariate Cox regression analysis showed that was used as an independent prognostic factor for hepatocellular carcinoma [hazard ratio=1.10, 95% confidence interval (1.050-1.156), <0.001]. The results of gene set enrichment analysis showed that was involved in pyrimidine metabolism, purine metabolism, aminoacyl tRNA biosynthesis, fatty acid metabolism, ppar signal transduction pathway, oocyte meiosis, amino acid and nucleotide sugar metabolism, RNA degradation, complement pathway, valine and isoleucine degradation, spliceosome, and other pathways. The high expression of is associated with the progression and prognosis of hepatocellular carcinoma. Therefore, this gene is expected to become a novel biomarker and a sort of target for biological therapy in hepatocellular carcinoma.